Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3402801 | 0.82 | CYP1A2 (0.58) | AKR1C3APEX1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL149582 | 0.82 | CYP1A2 (0.58) | AKR1C3APEX1CYP1A2CYP3A4CYP2C9 | |
| Guanidine SCHEMBL7165534 | 0.78 | CYP1A2 (0.50) | AKR1C3APEX1CYP1A2CYP3A4CYP2C9 | |
| Guanidine SCHEMBL7165528 | 0.78 | CYP1A2 (0.50) | AKR1C3APEX1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7008627 | 0.77 | AKR1C3 (0.53) | AKR1C3APEX1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7008624 | 0.77 | AKR1C3 (0.53) | AKR1C3APEX1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4260029 | 0.76 | AKR1C3 (0.42) | AKR1C3APEX1KDM4E | |
| SCHEMBL8746671 | 0.76 | AKR1C3 (0.68) | AKR1C3APEX1CYP2C9KDM4E | |
| SCHEMBL31666241 | 0.76 | AKR1C3 (0.68) | AKR1C3APEX1CYP2C9KDM4E | |
| SCHEMBL3893886 | 0.76 | AKR1C3 (0.68) | AKR1C3APEX1CYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709491-B2 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20060235032-A1 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | AIC246 AG & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235032-A1 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | TPMT, EIF2AK2, IRF3 | AKR1C3 4525/4885APEX1 2540/4885CYP1A2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.